The loss of CARA Therapeutics under GAAP for 9 months of 2020 amounted to $70.499 million, which is 9.3% lower compared to $77.762 million in the previous year. Revenue increased 49.5% to $22.993 million, against $15.375 million a year earlier.
The loss of CARA Therapeutics under GAAP for 9 months of 2020 amounted to $70.499 million, which is 9.3% lower compared to $77.762 million in the previous year. Revenue increased 49.5% to $22.993 million, against $15.375 million a year earlier. 
ir.caratherapeutics.com
English (US) 